<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OIN-17011426</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-05-17</date_registration>
      <primary_sponsor>Tianjin First Center Hospita </primary_sponsor>
      <public_title>Effect of co-infusion third party umbilical cord blood stem cells on haploidentical hematopoietic stem cell transplantation</public_title>
      <acronym />
      <scientific_title>Effect of co-infusion third party umbilical cord blood stem cells on haploidentical hematopoietic stem cell transplantation</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2017-05-22</date_enrolment>
      <type_enrolment />
      <target_size>haploidentical HSCT group:20;HLA-matched related HSCT group:20;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=19429</url>
      <study_type>Observational study</study_type>
      <study_design>Non randomized control</study_design>
      <phase>I (Phase I study)</phase>
      <hc_freetext>Hematological disease </hc_freetext>
      <i_freetext>haploidentical HSCT group:mobilized peripheral blood stem cells and low count of unrelated umbilical cord blood stem cells co-infusion;HLA-matched related HSCT group:mobilized peripheral blood stem cells alone;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Lv Hairong</firstname>
        <middlename />
        <lastname />
        <address>24 Fukang Road, Nankai District, Tianjin, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 18802235939</telephone>
        <email>18802235939@163.com</email>
        <affiliation>Department of Hematology, Tianjin First Center Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Zhao Mingfeng</firstname>
        <middlename />
        <lastname />
        <address>24 Fukang Road, Nankai District, Tianjin, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13752640369</telephone>
        <email>mingfengzao@sina.com</email>
        <affiliation>Department of Hematology, Tianjin First Center Hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. The patient or his/her legal guardians must sign a consent form;
2. The patients therapeutic regimen is approved by the hospital ethics committee;
3. Aged 18-55, males and females;
4. Hematopoietic diseases: acute myeloid leukemia, acute lymphoblastic leukemia, Chronic leukemia, severe aplastic anemia, myelodysplastic syndrome, have transplant indication;
5. No sever function diseases in heart, brain, lung, liver or kidney or other organs;
6. Acute leukemia achieve complete remission before transplantation and without CNS or extramedullary infiltration;
7. Karnofsky score is more than 60%, Eastern Cooperative Oncology Group (ECOG) physical status score 0-2;
8. Volunteers can be followed up for the treatment effect after transplantation. </inclusion_criteria>
      <agemin>18</agemin>
      <agemax>55</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. pregnant or lactating women;
2. severe organ dysfunction or disease, such as heart, liver, kidney and pancreas and other severe diseases and dysfunction;
3. Not suitable for HSCT;
4. uncontrolled active infection within 4 weeks;
5. other cancers;
6. have taken part in other clinical tests within 6 weeks;
7. have a history of central nervous system disease;
8. addicted to some drugs;
9. the central nervous system and other organs were treated with maximum tolerated radiotherapy within 6 months;
10. the researchers think it is not suitable for the test;
11. The donor does not meet the requirements: HIV positive, active hepatitis B or C, bone marrow disease, onset of mental illness, poison, drug addiction, refused to donate peripheral blood, etc. </exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>donor engraftment time;incidence and severity of graft-versus-host disease(GVHD),;recurrence rate of primary disease;DFS;OS;Treg;CD4+Th1, Th2, Th17;DC;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Fund of Tianjin First Center Hospital and Tianjin Health Bureau</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-04-26</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>